An observational study in Diabetes, Diabetic Retinopathy and Type 2 Diabetes Mellitus (T2DM), sponsored by Yufan Wang. Recruiting at 3 sites in China. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Yufan Wang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.
Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 46th largest by planned enrollment of the 137 observational ones that give a count, is one of 45 that started in 2025, is one of 137 observational ones, reaches primary completion later than 30 of the 116 other live ones, and was the 347th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:
China Medical University, China · Sites in China
Ages 50–75
CSL Behring · Sites in China
Ages 18+
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 25 · Phase 3 41 · Phase 4 52
First in 2002; this study’s year is marked. 45 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,920 is above the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 143 across the 280 interventional studies, 605 across the 137 observational. Of the 204 that completed or were terminated, 47 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 417 have an industry lead sponsor. The 10 most frequent:
Yufan Wang is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Yufan Wang has 2 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetes Mellitus with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06309082First Affiliated Hospital of Wenzhou Medical UniversityAssessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound | 2026-12 |
| NCT05105321Tang YidaCardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) | 2026-12 |
| NCT07489482Jiangsu HengRui Medicine Co., Ltd.A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection | 2026-12 |
| NCT06959784China-Japan Friendship HospitalAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | 2026-12-31 |
| NCT06958640China-Japan Friendship HospitalDa Qing Offspring Study | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 417 studies in Diabetes Mellitus with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to integrate clinical indicators and features of fundus images, combined with metabolomics, to construct an early warning model for diabetic retinopathy (DR) in type 2 diabetes. By combining clinical indicators with metabolomics, the investigators aim to establish a precise DR typing model based on the age of diabetes onset (early-onset diabetes, late-onset diabetes) and based on the coexistence with two types of diabetic macrovascular complications. A multidisciplinary collaboration will be conducted for comprehensive management of DR to control the progression of moderate-stage DR. Cloud-based patient rooms combined with continuous glucose monitoring (CGM) will further explore the role of integrated diabetes retinopathy ward management models in the management of patients undergoing diabetes retinopathy surgery, pioneering a new model for the management of advanced DR.
Type 2 Diabetes Mellitus Patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets the diagnostic criteria for type 2 diabetes in the "China Type 2 Diabetes Prevention and Treatment Guidelines (2020 Edition)";
Exclusion Criteria:
Those who have been diagnosed with type 1 or other types of diabetes;
Those with severe cardiac, pulmonary, hepatic, or renal insufficiency;
Those with mental confusion, speech disorders, or dementia, etc.;
Those who are unable to take care of themselves, bedridden, or have mobility impairments; ⑤ Women who are breastfeeding or pregnant;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An annual follow - up fundus examination is conducted. Metabolic differences are analyzed between the population with progressed diabetic retinopathy (DR) and those without progression. A predictive model for early warning of DR in type 2 diabetes is constructed to forecast the onset of DR one year later.
Diagnostic Test: Fundus Examination · Diagnostic Test: Metabolomics analysis
Seeking specific metabolites that can reflect diabetic retinopathy and its severity in early - onset and late - onset type 2 diabetes mellitus (T2DM).
Diagnostic Test: Fundus Examination · Diagnostic Test: Metabolomics analysis
Exploring a multidisciplinary model of chronic disease management for patients in the middle stage of diabetic retinopathy (DR), with both the endocrinology department and the ophthalmology department jointly developing standardized standard operating procedures for systemic and ocular examinations of metabolic diseases.
Diagnostic Test: Fundus Examination · Diagnostic Test: Metabolomics analysis
The establishment of an integrated ward for diabetic eye diseases. For patients with severe diabetic eye diseases who urgently need ophthalmic surgery in the short term but have poor blood glucose control, the ophthalmology and endocrinology departments jointly manage and treat the patients. Endocrinologists adjust the blood glucose - lowering treatment plan. After the blood glucose stabilizes, ophthalmic surgery is performed. Continuous glucose monitoring is used to closely observe blood glucose fluctuations during the hospital stay, including intraoperative blood glucose. After the surgery, both ophthalmologists and endocrinologists jointly follow up with the patients.
Diagnostic Test: Fundus Examination · Diagnostic Test: Metabolomics analysis
Performing fundus photography on patients to assess the progression of diabetic retinopathy (DR).
Conduct metabolomics testing at enrollment.
Fundus examination
Assess the severity of diabetic retinopathy (DR), and group accordingly. The high - risk DR cohort and the early - stage DR cohort have a fundus examination once a year; the mid - stage DR cohort has a fundus examination every six months; the late - stage DR cohort has a fundus examination every three months.
Time frame: Conduct examinations at enrollment and twelve months after enrollment.
Metabolomics analysis
By metabolomics, we aim to establish a precise DR typing model based on the age of diabetes onset (early-onset diabetes, late-onset diabetes) and based on the coexistence with two types of diabetic macrovascular complications so that we can better prevent and treat diabetic retinopathy.
Time frame: at enrollment
Triglycerides
Time frame: Conduct examinations at enrollment, six months after enrollment, and twelve months after enrollment.
Glycated Hemoglobin
Time frame: Conduct examinations at enrollment, six months after enrollment, and twelve months after enrollment.
Insulin levels
Time frame: Conduct examinations at enrollment, six months after enrollment, and twelve months after enrollment.
Total Cholesterol
Time frame: Conduct examinations at enrollment, six months after enrollment, and twelve months after enrollment.
Ran from Feb 2025 to primary completion in Aug 2025, 6 months.
Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's 6 months is below that.
Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.